TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

NCT07480785 · tracked via the Priya Life Science China tracker

Sponsor

Zhejiang University

Phase

Not applicable

Started

2026-01-16

Last updated

2026-03-18

Condition(s) studied

Uterine Fibroids (Leiomyoma)Ovarian TumorsGallstones

Investigational drug(s) / intervention(s)

transcutaneous electrical acupoint stimulationSham transcutaneous electrical acupoint stimulationtriple antiemetic drugs

transcutaneous electrical acupoint stimulation: Using the Huatuo brand electronic acupuncture therapy device (Model: SDZ-Ⅲ, produced by Suzhou Medical Equipment Co., Ltd., China), bilateral upper limb acupoints P6+L14 were selected. Approximately 30 minutes before anesthesia induction, the electrodes were connected with the initial current set at 1 milliampere and frequency at 2/100 Hz. The current intensity was gradually increased until the patient felt pain or reached the discomfort threshold (ranging between 6 to 10 mA), and the stimulation was maintained until the patient was discharged from the PACU.

Sham transcutaneous electrical acupoint stimulation: The same protocol was applied for percutaneous acupoint electrical stimulation, initiated before anesthesia induction with the minimum perceptible current (MPC) and terminated after 1 minute.

triple antiemetic drugs: Dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure.

Study summary

The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients.

The primary question it seeks to answer is:

Does TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Women scheduled for laparoscopic surgery ； * Aged 18-65 years； * ASA Class I-III； * Apfel score ≥ 3 (female sex, non-smoker, history of PONV and/or motion sickness). Exclusion Criteria: * Patients with a history of allergy to the investigational drug or contraindications； * Long-QT syndrome ； * Pregnancy, lactation, or menstruation ； * Current smoker； * Nausea/vomiting or use of antiemetics, opioids, or systemic corticosteroids within 24 h before surgery； * Requirement for post-operative sedation and mechanical ventilation ； * Severe renal or hepatic impairment ； * Psychiatric or neurological disorder ； * Vertebrobasilar insufficiency； * Vestibular disease； * Language or communication barrier ； * Skin lesion or infection at the acupoint stimulation site ； * Upper-limb nerve injury ； * Implanted cardiac pacemaker or defibrillator ； * Participation in another clinical trial within the past 4 weeks.

Primary outcome measure(s)

Number of Participants Experiencing Nausea,Retching and Vomiting within 24 hours after operation. — 2 hours post-operation, 6 hours post-operation, 24 hours post-operation
The number of episodes of nausea, retching and vomiting within 24 hours after operation

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang	Recruiting

More Zhejiang University trials in China

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients Recruiting

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer Recruiting

Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 Recruiting

A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery Starting soon

Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial Recruiting

Other trials for the same condition

Laparoscopic Myomectomy Based on a Fully Enclosed Protective Device: A Novel Surgical Technique Achieving Tumor-Free Protection Throughout the Entire Procedure Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07480785 on ClinicalTrials.gov ↗ ← All trials in China